State-of-the-Art in Renal Cell Carcinoma
A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Oncology".
Deadline for manuscript submissions: closed (15 April 2022) | Viewed by 4501
Special Issue Editor
2. Department of Anatomy, Canadian Memorial Chiropractic College, Toronto, ON M2H 3J1, Canada
3. Department of Pathology/Microbiology, Canadian Memorial Chiropractic College, Toronto, ON M2H 3J1, Canada
Interests: renal cell carcinoma; miRNA research; biomarker discovery; precision medicine; molecular diagnostics; translational research
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Renal Cell Carcinoma (RCC) is the most common adult kidney tumor with an aggressive and unpredictable prognosis. It is a heterogeneous tumor with distinctive genetic features for each histological subtype. The development of targeted therapies has significantly improved the metastatic renal cell carcinoma (mRCC) patient outcome. However, refractory cases were reported. Unfortunately, the triggering and controlling mechanisms for RCC tumor development and progression as well as the reasons for developing resistance are not yet fully understood.
Currently, there is no established RCC tumor marker for the early detection of the disease onset, progression, or response to treatment. Although several molecules were investigated, none was approved for clinical application. Therefore, there is an urgent need for developing a molecular biomarker that can be used alone or in combination with other clinical parameters to accurately predict disease outcome and response to treatment. This will significantly improve patient management. More understanding of RCC pathogenesis can pave the way toward the discovery of new targeted therapy.
Therefore, we are pleased to announce our Special Issue on “State-of-Art in Renal Cell Carcinoma” and to invite you to contribute to our special issue by submitting your research articles on renal cell carcinoma.
This special issue aims to provide a platform for a better understanding of the pathogenesis of this aggressive tumor as well as advances in health care/clinical practices in renal cell carcinoma to further optimize treatment choices and outcomes.
In this Special Issue, original research articles and reviews are welcome. Research areas may include (but not limited to) the following:
- Molecular basis (including the emerging role of non-coding RNAs) of renal cell carcinoma pathogenesis.
- Biomarker discovery including diagnostic, prognostic, and predictive biomarkers.
- Recent advances in diagnosis and therapeutic options.
- Molecular diagnostics
We are looking forward to receiving your contributions.
Dr. Heba Khella
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Renal Cell Carcinoma
- Metastasis
- Precision Medicine
- Targeted Therapy
- Biomarkers
- Non-coding RNA
- miRNA
- Prognosis
- Molecular Diagnostics
- Translational Research
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.
